Contents
Summary ……………………………………………………………………………………………………………………………………. 2
About the Author ………………………………………………………………………………………………………………………… 2
Disclaimer…………………………………………………………………………………………………………………………………… 3
Outcomes of Biomedtracker’s Large Impact Drug Catalysts from the Q4 2021 Outlook Report …………….. 6
Drugs …………………………………………………………………………………………………………………………………………. 8
Imbarkyd for Alport Syndrome ………………………………………………………………………………………………….. 8
Adlarity for Alzheimer’s Disease (AD) …………………………………………………………………………………………. 9
Sutimlimab for Autoimmune Hemolytic Anemia (AIHA) ……………………………………………………………… 10
Udenafil for Cardiovascular Disease …………………………………………………………………………………………. 11
Libtayo for Cervical Cancer ……………………………………………………………………………………………………… 12
MK-7264 for Chronic Cough …………………………………………………………………………………………………….. 13
Faricimab for Diabetic Macular Edema (Ophthalmology) ……………………………………………………………. 14
Oteseconazole for Fungal Infections – Non-Systemic ………………………………………………………………….. 15
Vutrisiran for Hereditary Transthyretin (hATTR) Amyloidosis with Polyneuropathy (Familial Amyloid Polyneuropathy) ……………………………………………………………………………………………………………………. 16
Omecamtiv Mecarbil (Oral) for Chronic Heart Failure – Reduced Ejection Fraction (Chronic HFrEF) …. 17
Lenacapavir for HIV / AIDS ………………………………………………………………………………………………………. 19
TransCon PTH for Hypoparathyroidism …………………………………………………………………………………….. 20
Daridorexant for Insomnia ………………………………………………………………………………………………………. 21
Fintepla for Lennox-Gastaut Syndrome (LGS; Epilepsy) ………………………………………………………………. 22
BMS-986213 for Melanoma …………………………………………………………………………………………………….. 23
Ryzneuta for Neutropenia / Leukopenia …………………………………………………………………………………… 24
LV-101 for Prader-Willi Syndrome ……………………………………………………………………………………………. 25
Mitapivat for Pyruvate Kinase Deficiency ………………………………………………………………………………….. 27
Ztalmy for Seizure Disorders (Epilepsy) …………………………………………………………………………………….. 28
EMB-001 for Smoking Cessation ………………………………………………………………………………………………. 29
Etrasimod for Ulcerative Colitis (UC) ………………………………………………………………………………………… 30
KSI-301 for Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology) ……………………….. 31
Faricimab for Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology) …………………….. 32
January 2022 / 5
Information Classification: General
Botulax for Wrinkles ………………………………………………………………………………………………………………. 33
Devices …………………………………………………………………………………………………………………………………….. 34
Aveir Leadless Pacemaker System For Cardiac Arrhythmias ………………………………………………………… 34
Deals ………………………………………………………………………………………………………………………………………… 36
Baylis to be Acquired by Boston Scientific …………………………………………………………………………………. 36
Sanifit to be Acquired by Vifor …………………………………………………………………………………………………. 36
Generate Life Sciences to be Acquired by CooperSurgical …………………………………………………………… 37